Maternal toxicity with continuous Nevirapine in pregnancy

A study was made by Pediatric AIDS Clinical Trials group Protocol 1022, where 38 antiretroviral-naive was randomly conducted on pregnant women at 10-30 weeks' gestation to nelfinavir or nevirapine with zidovudine plus lamivudine. Greater than expected toxicity and changes in nevirapine prescription was found and hence the study was suspended, showing results of toxicity seen 1 (5%) of 21 subjects randomized to nelfinavir and 5 (29%) of 17 subjects randomized to nevirapine (P = 0.07).